Abstract: The present invention relates to a process for the preparation of topiramate, intermediates in this process and a process for the preparation of these intermediates.

Abstract: The invention relates to a process for preparing N-(4?-cyano-3?-trifluoromethylphenyl)-3-(4?-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionamide (bicalutamide).

Abstract: The invention relates to novel processes for preparing penam derivatives, such as Tazobactam and derivatives thereof. The processes according to the invention encompass procedures for the protection and deprotection of the carboxylic group as well as for the oxidation of the sulfur moiety of penam derivatives. Additionally, the present invention relates to new intermediates for the production of penam derivatives, allowing the desired penam-derivatives to be formulated with high purity and in good yields.

Abstract: The present invention relates to a process for the preparation of topiramate, intermediates in this process and a process for the preparation of these intermediates.

Abstract: The present invention relates to a process for the preparation of Ropinirole.

Abstract: The invention relates to a process for preparing N-(4?-cyano-3?-trifluoromethyl)-3-(4?-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionamide (bicalutamide).

Abstract: The present invention relates to a method for producing 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine (lamotrigine) by cyclization reaction from &agr;-oxo-2,3-dichlorophenylacetamidino-aminoguanidino-hydrazone.

Abstract: The present invention relates to a method for producing 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine (lamotrigine) by cyclization reaction from &agr;-oxo-2,3-dichlorophenylacetamidino-aminoguanidino-hydrazone.

Abstract: The disclosure relates to a novel 8-substituted-9H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of formula I and pharmaceutically acceptable quaternary ammonium salts thereof, a process for preparing the same, a pharmaceutical composition containing a 8-substituted-9H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound, and a method of treatment using the pharmaceutical composition. A complete description of the compound of formula I is found in the specification. The compounds of the general formula I possess unique competitive AMPA/kainite antagonist properties making them useful in the treatment of diseases where inhibition of the AMPA/kainite receptors may a favorable effect.

Abstract: The invention relates to a novel process for preparing 1-[/2S/-methyl-3-mercaptopropionyl]-pyrrolidine-/2S/-carboxylic acid of the formula I ##STR1## in which 1-[/2S/-methyl-3-thiocyanatopropionyl]-pyrrolidine-/2S/-carboxylic acid of the formula II ##STR2## is dissolved in an aqueous mineral acid, the solution obtained is diluted with water and the 1-[/2S/-methyl-3-carbamoylthiopropionyl]-pyrrolidine-/2S/-carboxylic acid of the formula III ##STR3## that forms is hydrolized with an aqueous solution of a base.

Abstract: The invention relates to a novel process for preparing 1-[(2S)-3-mercapto-2-methyl-1-oxopropyl]-L-proline (captopril) of formula (I). ##STR1## which comprises hydrogenolysing 1-[(2S)-2-methyl-1-oxo-3-rhodanidopropyl]-L-proline of formula (II) ##STR2## in an inert solvent, in the presence of a catalyst, at a temperature of 50.degree. to 120.degree. C. under a pressure of 10.sup.5 to 10.sup.7 Pa.The above compound of formula (II) is new and can be prepared by acylating L-proline with a reactive acylating derivative of (2S)-2-methyl-3-rhodanido-propionic acid of formula (III).

Abstract: 4-[(3,4-Dialkoxyphenyl)alkyl]-2-imidazolidinone derivatives having the formula I ##STR1## wherein R.sup.1 stands for a cycloalkyl group containing from 3 to 6 carbon atoms or benzyl group;R.sup.2 stands for hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms;R.sup.3 stands for hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms;R.sup.4 stands for hydrogen atom, or an alkyl group containing from 1 to 4 carbon atoms or an alkoxycarbonyl group containing from 1 to 4 carbon atoms; andR.sup.5 stands for hydrogen atom or an alkoxycarbonyl group containing from 1 to 4 carbon atoms,are prepared by(a) reducing a hydantoin derivative having the general formula II, wherein R.sup.1 and R.sup.2 are as defined above, with lithium aluminum hydride in a neutral organic solvent, or(b) hydrogenating catalytically an 1,3-dihydro-2H-imidazol-2-one derivative having the general formula III, wherein R.sup.1 and R.sup.3 are as defined above, while the meaning of R.sup.